Importing Korean Hyaluronic Ampoule Serum to the US: MoCRA, FDA Registration, and Document Checklist

Importing a Korean hyaluronic ampoule serum into the US requires FDA facility registration under MoCRA, a compliant English-language label with INCI ingredient names, and a complete set of customs documents filed before the shipment reaches port. There is no pre-market FDA approval process for cosmetics, but the Korean factory must be registered with FDA and the product must be listed in Cosmetics Direct before a single unit can legally reach US buyers. Skipping facility registration or misfiling the Importer Security Filing are the two steps that most often lead to detention at US ports.

The Regulatory Shift: What MoCRA Means for Korean Skincare Exporters

The Modernization of Cosmetics Regulation Act (MoCRA), signed into law in December 2022, is the most significant overhaul of US cosmetics regulation in more than 80 years. According to ArentFox Schiff LLP, FDA began enforcing MoCRA's facility registration and product listing requirements on July 1, 2024. For Korean skincare exporters, this changes the entry requirements in a fundamental way: the Korean factory must be registered with FDA before any product reaches US buyers, and each serum must be listed in FDA's Cosmetics Direct system.

By January 1, 2025, FDA's Cosmetics Direct system showed 9,528 active facility registrations and 589,762 product listings, according to Elchemy. That adoption rate signals that registration is now the expected baseline — unregistered facilities stand out and face a higher risk of scrutiny at US ports.

Korean cosmetics exports reached a record $10.28 billion globally in 2024, with the United States as the largest single export market, according to The Korea Herald. Hyaluronic serums and ampoules represent a significant share of that export value. Market access to the US is real, and so is the compliance threshold that comes with it.

The FDA Registration Path for Korean Manufacturers

Under MoCRA, every facility that manufactures or processes cosmetics for US distribution must register with FDA — this includes Korean factories. Per Crowell & Moring LLP, registrations must be renewed every two years and updated within 60 days of any material changes to the facility's information.

The first action is facility registration through FDA's Cosmetics Direct portal at direct.fda.gov. Registration is free. Required information includes the facility owner name, the FDA Establishment Identifier (FEI) number, all brand names manufactured at the facility, and the product categories, per US FDA.

Foreign manufacturers must also designate a US agent. Per Crowell & Moring LLP, this US agent assists FDA in communications, responds to product questions, helps schedule inspections, and receives FDA documents on behalf of the Korean establishment. The US agent must be physically located in the United States and reachable during US business hours.

As a US importer evaluating a Korean supplier, ask for the factory's FEI number and verify it in FDA's Cosmetics Direct portal before placing your first order. An unregistered factory cannot legally supply product for the US market under MoCRA.

Product Listing and the Responsible Person Role

After the facility is registered, the Responsible Person must list each marketed product in Cosmetics Direct. Per Crowell & Moring LLP, the Responsible Person is the manufacturer, packer, or distributor whose name appears on the cosmetic product label. For imported products, this role typically falls to the US importer.

Product listings must be submitted in SPL (Structured Product Labeling) format and must include the complete INCI ingredient list, product categories, and the FEI numbers of all facilities where the product is manufactured or processed. Listings must be updated annually.

Taking on the Responsible Person role also carries ongoing reporting obligations. Per Elchemy, the Responsible Person must report serious adverse events to FDA no later than 15 business days after receiving a report. Serious adverse events include hospitalizations, permanent disability, and life-threatening conditions. All adverse event records must be retained for 6 years.

This is a legally defined compliance role under MoCRA — not simply a label designation. Understand these obligations fully before accepting the Responsible Person role, and establish an internal process for adverse event monitoring from the start.

Safety Substantiation: What Your Korean Factory Must Document

MoCRA requires Responsible Persons to maintain safety substantiation documentation on file and available upon FDA request. Per Zignify, this documentation must include a toxicological assessment of each ingredient, stability testing (3 months accelerated and 12 months real-time), preservative challenge testing, and microbial and heavy metals testing. Pre-market FDA submission is not required, but the documentation file must be complete and ready for inspection.

For a hyaluronic ampoule serum with 2% hyaluronic acid and 5% niacinamide, ask your Korean factory for their complete safety data package and confirm that each test was conducted by an accredited laboratory. Batch traceability records — linking finished units back to raw material lots — are also part of a sound safety file.

FDA cGMP standards for cosmetics are expected in a final rule by December 29, 2025, per Zignify. ISO 22716 — the international cosmetics GMP standard covering personnel training, facility hygiene, raw material control, batch traceability, and complaint handling — closely aligns with FDA's expected cGMP requirements. Korean factories with ISO 22716 certification are in a strong position for that forthcoming rule.

Label Language and Claim Compliance

Per Unicargo, labels are the top cause of FDA import holds for cosmetics. For a product currently labeled in Korean, the US label must be rebuilt from the ground up. US cosmetic labels require INCI ingredient names listed in descending order of predominance by weight, all in English. Labels must also include the net quantity in both US (fl oz) and metric (mL) units, the product identity, and the manufacturer or distributor name and address.

As of December 29, 2024, per ArentFox Schiff LLP, the label must include domestic contact information — a physical address, phone number, or website — through which the Responsible Person can receive adverse event reports from consumers.

The most consequential labeling decision is claim language. Per ALTAMEET, claims that assert structural skin function — "stimulates collagen production," "treats acne," "repairs skin cells," or "reduces wrinkles" in the sense of structural function — cause FDA to classify the product as an unapproved drug, potentially resulting in shipment refusal at US ports. FDA screens shipments through its automated PREDICT system upon arrival, and drug-claim language on cosmetic labels is a primary detention trigger.

Acceptable cosmetic claims focus on appearance: "hydrates skin," "smooths the appearance of fine lines," "helps skin look dewy and more radiant." Review every marketing claim line with this distinction in mind before finalizing the US label.

Customs Documents Required at US Ports

Getting a hyaluronic serum shipment through US Customs and Border Protection (CBP) and FDA port screening requires a specific set of documents prepared before the shipment departs Korea. Per CrimsonLogic North America, required documents include a commercial invoice with HS code 3304.99, quantities, value, and country of origin; a bill of lading or air waybill; a packing list; FDA Prior Notice filed before arrival; a certificate of origin; a certificate of analysis; a free sale certificate where applicable; and labeling samples for compliance verification.

For ocean shipments from Korea, the Importer Security Filing (ISF/10+2) must be submitted to CBP at least 24 hours before cargo is loaded onto the vessel, per Unicargo. Missing this window gives CBP authority to issue penalties and detain the cargo.

FDA screens cosmetics shipments through its automated PREDICT system upon arrival at US ports, per ALTAMEET. Unregistered facilities, incorrect labeling, and drug-claim language are the primary triggers for FDA detention. Engaging a customs broker experienced in FDA Prior Agency (PGA) data requirements is the practical way to ensure Prior Notice and ISF filings are complete and submitted on time.

KORUS FTA: Zero Duty for Qualifying Korean Serums

Hyaluronic ampoule serums classified under HTS code 3304.99 carry standard duty rates of 4.9% to 5.8% under the general tariff schedule, per CrimsonLogic North America. Under the Korea–US Free Trade Agreement (KORUS FTA), in effect since March 15, 2012, qualifying Korean-origin cosmetics enter the US at 0% duty, per US Customs and Border Protection.

To claim the preferential rate, the importer provides a certificate of origin documenting that the product meets KORUS rules of origin. No prescribed form is required by the Korean Customs Service — the certificate of origin statement can appear on the commercial invoice or as a separate document. For a serum manufactured in Korea from Korean raw materials, establishing KORUS origin is typically straightforward.

On a container shipment of hyaluronic serum, the KORUS duty savings compared to the standard rate are material. Ask your customs broker to confirm the FTA claim is filed correctly on the CBP entry form, and keep the certificate of origin on file for potential CBP audit.

Frequently Asked Questions

The questions below address what US importers and sourcing managers ask most when evaluating a Korean hyaluronic ampoule serum for the first time.

Does my Korean OEM manufacturer need FDA registration before I can legally sell their hyaluronic serum in the US?

Yes. Under MoCRA, every facility that manufactures or processes cosmetics for US distribution must register with FDA — including Korean factories. Per Crowell & Moring LLP, registration is submitted free of charge through FDA's Cosmetics Direct portal at direct.fda.gov. Ask your Korean factory for their FDA Establishment Identifier (FEI) number and verify active registration status in Cosmetics Direct before placing your first order. If the factory is not registered, FDA can detain the shipment at the port of entry under MoCRA enforcement, which began July 1, 2024.

What label changes must I make to a Korean ampoule serum before importing it to the US?

The US label must be rebuilt in English with INCI (International Nomenclature of Cosmetic Ingredients) names for all ingredients, listed in descending order of predominance by weight, per Unicargo. The label must also include the product identity, net quantity in both US (fl oz) and metric (mL) units, and the manufacturer or distributor name and address. As of December 29, 2024, per ArentFox Schiff LLP, the label must include domestic contact information — a physical address, phone number, or website — through which the Responsible Person can receive adverse event reports from consumers. Korean-only labeling does not comply with the Fair Packaging and Labeling Act or MoCRA.

What is a Responsible Person under MoCRA, and what liabilities does a US importer take on by accepting that role?

The Responsible Person is the manufacturer, packer, or distributor whose name appears on the US cosmetic product label — for imported products, this is typically the US importer. Per Crowell & Moring LLP, the Responsible Person must list each product in FDA's Cosmetics Direct system, maintain safety substantiation documentation, and report serious adverse events to FDA within 15 business days of receiving a report. Serious adverse events include hospitalizations, permanent disability, and life-threatening conditions. Adverse event records must be retained for 6 years. This is a legally defined compliance role under MoCRA, not simply a label credit — understand these obligations fully before accepting the designation.

How do I use the KORUS FTA to get zero duty on Korean serum imports, and what certificate of origin is required?

The Korea–US Free Trade Agreement (KORUS FTA), in effect since March 15, 2012, reduces the standard duty rate of 4.9–5.8% for cosmetics under HTS 3304.99 to 0% for qualifying Korean-origin products, per US Customs and Border Protection. To claim the preferential rate, the importer provides a certificate of origin documenting that the product meets KORUS rules of origin. No prescribed form is required by the Korean Customs Service — the statement can appear on the commercial invoice or as a separate document. Ask your customs broker to confirm the FTA claim is filed correctly on the CBP entry form and keep the certificate of origin on file for potential CBP audit.

Which marketing claims about a hyaluronic acid serum will get my shipment flagged at US customs as an unapproved drug?

Claims that assert structural skin function trigger drug classification under the FD&C Act. Per ALTAMEET, examples include "stimulates collagen production," "treats acne," "repairs skin cells," and "reduces wrinkles" in the sense of structural function. FDA screens shipments through its automated PREDICT system, and drug-claim language on cosmetic labels is one of the primary detention triggers. Safe cosmetic claims focus on appearance: "hydrates skin," "smooths the appearance of fine lines," "helps skin look dewy and more radiant." Review every marketing claim line before finalizing your US label — the distinction between a cosmetic and an unapproved drug is determined by language, not by the ingredient itself.

Ready to Export Your Korean Serum to the US Market?

Selling a Korean hyaluronic ampoule serum in the US now requires FDA facility registration under MoCRA, product listing in Cosmetics Direct, a compliant English-language label, and a complete set of customs documents filed before the shipment arrives at port. Running these steps in parallel — starting with factory registration verification, label review, and safety documentation before your first container ships — is what keeps market entry on schedule and avoids detention delays.

As a Korean trade platform, we help hyaluronic serum exporters connect with FDA-registered Korean manufacturers, review US label compliance before shipment, and coordinate customs documentation for smooth US port clearance.

This information is provided for reference only. FDA regulations, MoCRA requirements, and CBP procedures change over time. Always confirm current obligations directly with the FDA, US Customs and Border Protection, and a licensed customs broker before acting on this information.